Stock ARCH ARCH BIOPARTNERS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Arch Biopartners Inc. Toronto S.E.

Equities

ARCH

CA03938C1041

Delayed Toronto S.E.
Other stock markets
 09:38:30 2024-07-16 am EDT 		5-day change 1st Jan Change
1.63 CAD +0.31% Intraday chart for Arch Biopartners Inc. -1.21% +10.14%
Jun. 27 Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product MT
Jun. 27 Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
AQ
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
AQ
Arch Biopartners Inc. - St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
AQ
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
AQ
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
AQ
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
AQ
Grant of Options to Directors and Officers
AQ
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
AQ
Shares for Interest Debt Settlement
AQ
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
AQ
Arch Biopartners : 2023 Q3 Interim Financial Statements
PU
Arch Biopartners Engages Independent Trading Group as Market Maker
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACHFF Stock
  4. ARCH Stock
  5. News Arch Biopartners Inc.
  6. Press Releases